Secondary Hypogonadism: Genetics and Family History

What Makes Hypogonadism "Secondary" and Why Genetics Matter

Secondary hypogonadism originates above the testes. The hypothalamus or pituitary fails to produce adequate gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), or follicle-stimulating hormone (FSH), and testosterone output drops as a consequence. The 2018 Endocrine Society guideline defines the biochemical threshold as a total testosterone below 300 ng/dL confirmed on two morning samples, paired with LH that is low or inappropriately normal (typically <8 mIU/mL) [1].

Acquired causes (obesity, opioids, pituitary tumors) account for most adult-onset cases. But a meaningful subset traces back to heritable gene defects that impair GnRH neuron migration, GnRH secretion, or gonadotropin synthesis. These congenital forms often present as delayed or absent puberty, yet milder variants can escape detection until a man in his twenties or thirties is evaluated for infertility or fatigue. A 2019 review in Nature Reviews Endocrinology identified pathogenic variants in over 50 genes across congenital hypogonadotropic hypogonadism (CHH) cohorts [2]. Understanding the genetic architecture of secondary hypogonadism matters because it changes the diagnostic workup, predicts fertility potential, and determines whether the condition might reverse spontaneously.

The Genetic Architecture of Congenital Hypogonadotropic Hypogonadism

CHH splits into two clinical categories depending on smell. Kallmann syndrome combines GnRH deficiency with anosmia or hyposmia. Normosmic idiopathic hypogonadotropic hypogonadism (nIHH) presents with intact olfaction. Both share overlapping genetic causes, though certain genes track preferentially with one phenotype.

The largest single-gene contributor to Kallmann syndrome is ANOS1 (previously KAL1), which encodes anosmin-1, a glycoprotein that guides GnRH neuron migration along olfactory axons during embryonic development [3]. ANOS1 mutations follow X-linked recessive inheritance and account for 5 to 10% of Kallmann syndrome diagnoses. Only males are affected clinically, though carrier females may show subtle olfactory deficits.

FGFR1 mutations are the most common autosomal cause. They act in an autosomal dominant pattern with variable expressivity, meaning two family members carrying the same variant can present very differently: one with complete pubertal failure, another with only partial delay. A 2012 study in the Journal of Clinical Endocrinology & Metabolism found FGFR1 loss-of-function variants in approximately 10% of a large CHH cohort [4].

Other well-validated genes include PROKR2/PROK2 (prokineticin signaling, roughly 5-9% of cases), GNRHR (the GnRH receptor itself, 3-5% of nIHH), CHD7 (also implicated in CHARGE syndrome), and TAC3/TACR3 (neurokinin B pathway). Each gene contributes a small fraction of total cases, which explains why roughly half of CHH patients still receive no definitive molecular diagnosis with current testing panels [2].

Oligogenic Inheritance: Why One Gene Is Often Not Enough

Classical Mendelian inheritance (one gene, one phenotype) does not fully explain CHH. A 2012 paper in the New England Journal of Medicine highlighted that some patients carry pathogenic variants in two or more genes simultaneously, a model termed oligogenic inheritance [5]. In these patients, a single heterozygous variant in FGFR1 might produce only constitutionally delayed puberty, while the addition of a second hit in PROKR2 or IL17RD tips the balance toward complete GnRH deficiency.

This gene-dose model explains several clinical puzzles. It accounts for incomplete penetrance within families, where the same FGFR1 variant causes Kallmann syndrome in one sibling and nothing clinically apparent in a parent. It also explains the variable expressivity that makes genetic counseling difficult. Dr. Nelly Pitteloud, whose group at the University of Lausanne has studied CHH genetics extensively, has stated: "The phenotypic spectrum of CHH is far broader than we appreciated. Oligogenic inheritance means that family history alone will miss many carriers" [5].

The clinical takeaway is that negative results on single-gene testing do not exclude a genetic cause. Multi-gene panel testing or whole-exome sequencing increases diagnostic yield. A 2015 analysis published in the Journal of Clinical Endocrinology & Metabolism demonstrated that panel-based next-generation sequencing identified pathogenic or likely pathogenic variants in 43% of 48 previously unresolved CHH patients [6].

How Family History Points Toward a Genetic Cause

Not every man with secondary hypogonadism needs genetic testing. But certain family patterns should trigger referral to an endocrinologist or geneticist.

The strongest red flag is a first-degree relative with delayed or absent puberty. A 2011 cohort study found that approximately 14% of CHH probands had at least one affected family member, with another 12% reporting a relative with isolated anosmia or delayed puberty that self-resolved [3]. Constitutional delay of growth and puberty (CDGP) may, in some families, represent a milder allelic variant of the same genetic disruption that produces full CHH in other relatives.

Other family history clues worth documenting:

• Anosmia or hyposmia in siblings, parents, or uncles (suggests ANOS1 or FGFR1 pathway involvement)
• Cleft lip or palate (associated with FGFR1 and FGF8 variants)
• Hearing loss (seen with CHD7 mutations, also linked to CHARGE syndrome)
• Renal agenesis (ANOS1 and FGF signaling genes)
• Skeletal anomalies such as synkinesia (mirror movements of the hands), which occurs specifically with ANOS1 mutations
• Infertility or small testicular volume in male relatives

The Endocrine Society guideline recommends measuring serum testosterone in men with symptoms and relevant risk factors, but does not mandate routine genetic testing for all secondary hypogonadism [1]. Genetic evaluation is most informative when the onset is pre-pubertal, when LH and FSH are persistently low (not just borderline), and when acquired causes have been excluded by MRI and metabolic screening.

Distinguishing Genetic From Acquired Secondary Hypogonadism

The distinction matters clinically because it directs treatment and sets realistic expectations for fertility.

Acquired causes are far more common in adult men. The Endocrine Society 2018 guideline lists obesity, type 2 diabetes, opioid use, hyperprolactinemia, and pituitary masses as leading acquired etiologies [1]. Functional hypogonadotropic hypogonadism, driven by obesity and metabolic syndrome, accounts for up to 40% of cases in men with BMI above 30, according to data from the European Male Ageing Study (EMAS) (N=3,369) [7]. These cases frequently reverse with weight loss.

Genetic secondary hypogonadism tends to present earlier and with specific associated features. Key differentiators include:

• Age at onset: pre-pubertal or peri-pubertal points toward CHH; onset after age 30 with prior normal puberty suggests acquired etiology
• Testicular volume: bilateral testes <4 mL in an adult male strongly suggest longstanding gonadotropin deficiency
• Olfaction: formal smell testing (UPSIT) should be part of the workup. Hyposmia or anosmia is present in roughly 50% of CHH patients
• MRI findings: normal hypothalamic-pituitary anatomy on MRI, combined with absent olfactory bulbs, confirms Kallmann syndrome
• Response to treatment withdrawal: approximately 10 to 20% of genetically confirmed CHH patients achieve sustained gonadotropin recovery after discontinuing therapy, a phenomenon not seen in structural pituitary disease [2]

Dr. Stephanie Page, a leading researcher in male reproductive endocrinology at the University of Washington, has noted: "The boundary between constitutional delay and permanent CHH is not always clear in adolescence. Some patients declared 'delayed' at 14 will still have low testosterone at 25, and genetic testing can help resolve that ambiguity earlier" [8].

Genetic Testing: What Is Available and When to Order It

Current genetic evaluation for CHH involves targeted gene panels, whole-exome sequencing (WES), or, in research settings, whole-genome sequencing. Commercially available panels from laboratories such as Invitae, GeneDx, and Blueprint Genetics cover 30 to 70 CHH-related genes and cost between $250 and $2,000 depending on insurance coverage.

The diagnostic yield of these panels sits at approximately 40 to 50% [6]. That number is expected to rise as more genes are validated and as laboratories improve detection of structural variants and copy number changes that standard sequencing can miss.

Recommended indications for genetic testing in secondary hypogonadism:

1. Absent or incomplete puberty with low gonadotropins and no acquired cause
2. Anosmia or hyposmia paired with hypogonadism at any age
3. Family history of CHH, Kallmann syndrome, anosmia, or unexplained infertility
4. Associated syndromic features (cleft palate, hearing loss, renal anomalies, synkinesia)
5. Young men (<30) with persistently low LH/FSH and testosterone below 150 ng/dL after excluding pituitary mass and hyperprolactinemia

A negative genetic test does not rule out a hereditary component. It may reflect gaps in current gene panels, oligogenic interactions below detection thresholds, or epigenetic mechanisms not captured by sequencing. The American College of Medical Genetics and Genomics (ACMG) recommends that genetic results be interpreted alongside clinical data, never in isolation [9].

How Genetic Findings Influence Treatment Decisions

Treatment of secondary hypogonadism differs from primary hypogonadism in one critical respect: the testes are structurally intact. This means fertility-preserving therapies that stimulate endogenous gonadotropin release or replace gonadotropins directly are viable options.

For men with genetically confirmed CHH who desire fertility, pulsatile GnRH therapy (where available) or combined human chorionic gonadotropin (hCG) plus recombinant FSH is the standard approach. A 2013 meta-analysis in Fertility and Sterility (13 studies, 580 men) reported that 75% of CHH patients treated with gonadotropins achieved spermatogenesis, though median sperm concentrations remained below normal at approximately 5.9 million/mL [10].

Predictors of better fertility outcomes include larger baseline testicular volume (above 4 mL), prior spontaneous puberty (even partial), and absence of cryptorchidism. Genetic subtype also matters. Patients with GNRHR mutations tend to have milder phenotypes with better treatment response, while those with ANOS1 mutations and a history of cryptorchidism typically need longer gonadotropin courses (12 to 24 months) before sperm appear in the ejaculate [10].

For men not pursuing fertility, exogenous testosterone is appropriate. However, the 2018 Endocrine Society guideline cautions that testosterone therapy suppresses spermatogenesis and should be discussed thoroughly with younger patients who may want children in the future [1]. Alternatives like enclomiphene (a selective estrogen receptor modulator that stimulates pituitary LH release) and low-dose hCG monotherapy preserve testicular function while raising serum testosterone.

Genetic counseling becomes relevant once a pathogenic variant is identified. For X-linked ANOS1 mutations, all daughters of an affected male will be carriers, and each son of a carrier female has a 50% chance of being affected. For autosomal dominant genes like FGFR1, each child of an affected parent has a 50% chance of inheriting the variant, though penetrance is incomplete.

The Reversibility Question: Can Genetic CHH Resolve on Its Own?

One of the more surprising findings in CHH research is that the condition is not always permanent. Studies have documented spontaneous reversal of gonadotropin deficiency in 10 to 22% of patients, even in those with identified genetic mutations. A 2014 study in the Journal of Clinical Endocrinology & Metabolism followed 50 men with CHH who discontinued testosterone or gonadotropin therapy and found that 10 (20%) sustained normal testosterone levels (>300 ng/dL) with normal LH pulsatility at 12 months off treatment [11].

Reversal has been reported across multiple genotypes, including FGFR1, PROKR2, and TAC3/TACR3. ANOS1-associated Kallmann syndrome, by contrast, appears less likely to reverse, possibly because the underlying GnRH neuron migration defect is structural rather than functional.

Clinicians should trial treatment withdrawal in selected CHH patients, particularly those who achieved normal testosterone on low-dose gonadotropin therapy and those who entered puberty spontaneously (even if incompletely) before diagnosis. The reversal may not be permanent. Relapse occurs in roughly one-third of those who initially recover, so long-term monitoring every 6 to 12 months is necessary [11].

Epigenetics and Non-Mendelian Mechanisms

Not all familial clustering of secondary hypogonadism fits classical genetic models. Epigenetic modifications (DNA methylation, histone changes) affecting GnRH neuron function or pituitary gonadotrope differentiation represent an emerging area of investigation. A 2019 study in Nature Reviews Endocrinology noted that environmental exposures during fetal development, including endocrine-disrupting chemicals such as phthalates and bisphenol A, may alter methylation patterns in genes governing the hypothalamic-pituitary-gonadal axis [2].

These epigenetic changes can, in theory, be transmitted across generations without altering DNA sequence. Research in animal models has shown that paternal high-fat diet exposure alters offspring hypothalamic gene expression and GnRH pulse frequency. Human data remain preliminary, but the concept helps explain families where multiple members have low testosterone or delayed puberty without a detectable Mendelian mutation.

Current clinical practice does not include epigenetic testing. This may change as methylation arrays become cheaper and as specific epigenetic signatures are validated against CHH phenotypes. For now, a negative gene panel in a patient with strong family history should prompt consideration of oligogenic inheritance, copy number variants, and these non-coding regulatory mechanisms rather than dismissal of a genetic contribution.

Serum testosterone should be rechecked every 6 to 12 months in men with genetically confirmed CHH, regardless of whether they are on active treatment, because spontaneous reversal remains possible even years after initial diagnosis [11].